|

May 2013 Vol. 2 Issue 5
Other viewing option
Abstract
• Full
text
•Reprint
(PDF) (154 KB)
Search Pubmed for articles by:
Tayeb MMS
Other links:
PubMed Citation
Related articles in PubMed
|
|
Global Advanced Research Journal
of Medicine and Medical Sciences (GARJMMS) ISSN: 2315-5159
May 2013 Vol. 2(5), pp.
120-124
Copyright © 2013 Global Advanced
Research Journals
Case Report
|
Allergy to
Montelukast Sodium Treated Effectively by Protracted
Oral Desensitization: First case report
Moufag Mohammed Saeed Tayeb
ABFM, Allergy Diploma (NRTC – UK), Assistant
Professor and Consultant, King Abdul-Aziz
University, Jeddah, Saudi Arabia.
E-mail
moufagta@yahoo.com
Accepted 11 April, 2013
|
|
Abstract |
|
Antileukotrines such as
Montelukast Sodium play a significant role in asthma
control. IgE mediated hypersensitivity reactions to
Montelukast is very rarely reported. To explore the
efficacy of oral desensitization in Montelukast
hypersensitivity. A 30 year old Saudi woman with
uncontrolled asthma despite maximum pharmacological
therapy presented to allergy clinic with recurrent
symptoms of lip swelling, maculopapular skin rash
and shortness of breath a few minutes after taking
Montelukast 10 mg orally. Eventually, she was
diagnosed as a case of hypersensitivity reaction
type I to Montelukast. As a consequence of her
uncontrolled asthma symptoms and as no other
alternative Antileukotrine was available, it was
decided to start an oral desensitization with
Montelukast. Phase I desensitization was conducted
in the clinic by gradually increasing doses of oral
Montelukast starting from 0.001 mg up to 1 mg. Phase
II desensitization was conducted at home with
increasing doses starting from 1mg up to 10 mg/day.
Patient was followed by frequent clinic visits,
emails and phone calls. Desensitization phases I was
successful over a period of 3 hours with minimal
reactions. Desensitization phase II was prolonged
due to the occurrence of several allergy symptoms of
shortness of breath, dizziness and itching, which
were controlled partially with oral antihistamines,
prednisolone and maintaining the same dose until
clear. Finally, after 12 weeks, the patient was able
to tolerate pharmaceutical doses of Montelukast at
10 mg safely and managed to gain a better asthma
control. To our knowledge, this is the first case
report of effective oral Montelukast desensitization
in an asthmatic patient with hypersensitivity type 1
to Montelukast. Although such allergic reaction to
antileukotrines is rare, it should be recognized by
healthcare providers. If no alternative therapy is
available to control asthma symptoms, oral
desensitization could stand as a valid effective
therapeutic option.
Keywords:
Montelukast sodium, Oral Desensitization, asthma
|
| |
|